Search for: "T. E.D. C."
Results 61 - 80
of 964
Sort by Relevance
|
Sort by Date
10 Feb 2023, 4:44 am
Putting aside the idiosyncratic chapter by the late Professor Berger, most of the third edition of the Reference Manual presented guidance on many important issues. [read post]
8 Feb 2023, 6:15 am
Oeser (E.D. [read post]
11 Jan 2023, 11:33 am
MOHELA, No. 4:21-CV-00083, 2021 WL 3206691, at *3 (E.D. [read post]
12 Dec 2022, 10:57 am
., No. 6:20-cv-00176 (E.D. [read post]
7 Dec 2022, 6:02 am
Turner, No. 2:20-cv-04073-JDW (E.D. [read post]
4 Dec 2022, 5:20 am
P. 26(c)(1). [read post]
14 Nov 2022, 11:30 am
See Dep't of Com. v. [read post]
14 Nov 2022, 5:01 am
[C.] [read post]
19 Oct 2022, 9:42 am
Karloutsos (E.D. [read post]
15 Oct 2022, 8:27 am
Supp. 3d 394, 424 (E.D. [read post]
5 Oct 2022, 6:51 am
§ 1391(c). [read post]
3 Oct 2022, 12:04 pm
In “Cheng’s Proposed Consensus Rule for Expert Witnesses,”[1] I discussed a recent law review article by Professor Edward K. [read post]
15 Sep 2022, 9:04 am
Hugham Chan the E.D. [read post]
24 Aug 2022, 5:01 am
Verner[20] said was at least constitutionally permissible (even though it wouldn't be constitutionally mandatory here, for reasons discussed in Part II). [read post]
16 Aug 2022, 6:24 am
Bank of Am., 2022 WL 3141863 (E.D. [read post]
3 Aug 2022, 5:01 am
P'ship I, No. 4:20-CV-1099-LPR, 2022 WL 2276835 (E.D. [read post]
19 Jul 2022, 2:59 pm
In the following guest post, the authors revisit the question of whether or not securities class action lawsuits against development-stage biotech companies are likelier to survive a motion to dismiss compared to securities suits against other kinds of companies. [read post]
18 Jul 2022, 2:21 pm
DOJ (E.D. [read post]
12 Jul 2022, 7:01 am
AOL (E.D. [read post]
9 Jul 2022, 11:48 am
The court says Section 230 doesn’t apply. [read post]
